J+D Forecasting at ASCO 2019

With a theme of Caring for Every Patient, Learning from Every Patient, 2019 was another record-breaking year for ASCO® with over 42,000 total attendees.

Advances in targeted therapies for pancreatic, prostate, and paediatric cancers, as well as new approaches to overcoming limited access to cancer care were among the topics highlighted in the meeting’s official Press Program.

J+D representatives travelled to Chicago for the 55th Annual Meeting of the American Society of Clinical Oncology to speak to delegates about our Onco+ oncology forecasting software tool.

We spoke to delegates about their forecasting challenges and introduced them to what Excel add-in Onco+ had to offer – time saving with easy to build models, supporting sophisticated oncology forecasting with all variables built in, plus control by removing reliance on third party consultants.

Find out more about Onco+, one of our FC+ software add-ins here.

About ASCO:

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents nearly 45,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation.

more insights

Our Pharmaceutical Forecasting Predictions for 2024

As the pharmaceutical industry contends with growing financial pressures, we examine its strategic outlook for 2024. How does the sector intend to align with projected commercial objectives while continuing to meet patient needs and what are the implications for forecasting teams?

Read more >